Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ. Abou-Alfa GK, et al. Among authors: lin cc. Cancer Chemother Pharmacol. 2011 Aug;68(2):539-45. doi: 10.1007/s00280-011-1671-3. Epub 2011 May 19. Cancer Chemother Pharmacol. 2011. PMID: 21594722 Clinical Trial.
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Lin CC, et al. Cancer Chemother Pharmacol. 2009 May;63(6):1065-71. doi: 10.1007/s00280-008-0811-x. Epub 2008 Sep 16. Cancer Chemother Pharmacol. 2009. PMID: 18795291 Clinical Trial.
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Lin CC, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):167-75. doi: 10.1007/s00280-009-1020-y. Epub 2009 May 16. Cancer Chemother Pharmacol. 2009. PMID: 19449006 Clinical Trial.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. Reynolds KL, et al. Among authors: lin cc. BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6. BMC Cancer. 2017. PMID: 28899363 Free PMC article. Clinical Trial.
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK. El Dika I, et al. Among authors: lin cc. Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31. Oncologist. 2019. PMID: 30598500 Free PMC article. Clinical Trial.
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH. Hsu CH, et al. Among authors: lin cc. Anticancer Res. 2002 Nov-Dec;22(6B):3621-7. Anticancer Res. 2002. PMID: 12552966 Clinical Trial.
6,679 results